Delivery Order SPE2DB25D3109-SPE2DB25FPKQE
- Not listed
- The Defense Logistics Agency awarded a $17,257.88 delivery order to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Enbrel 50 mg/ml syringes. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a $14.5K delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of ENBREL 25 mg/0.5 ml syringes. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $5,504.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with an ultimate completion date of August 19, 2025. This non-set-aside contract represents a direct award to the pharmaceutical distributor, which maintains its corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999...
- The Defense Logistics Agency awarded a $10,359.88 delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 16, 2025. The contract was competitively awarded with no set-aside designation and is structured as a firm fixed-price delivery order. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $37,120.42 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and represents a non-set-aside competitive award. AmerisourceBergen's corporate office, located in Conshohocken, Pennsylvania, will serve as the place of performance. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for ENBREL 50 mg/ml syringes valued at $29,284.84. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled at the contractor's Conshohocken, Pennsylvania facility with...
- The Defense Logistics Agency awarded a $13,737.99 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, with an ultimate completion date of September 12, 2025. This contract represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and operates as a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $20,608.70 to AmerisourceBergen Drug Corp for ENBREL 50 mg/mL syringes, with an ultimate completion date of August 12, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor and critical vendor for...
- The Defense Logistics Agency awarded a $31,043.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml syringes, with an ultimate completion date of September 5, 2025. This non-set-aside award was made competitively and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion vehicle running through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $19,183.16 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL syringes, effective June 2, 2025, with completion targeted for June 3, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- SPE2DB25D3109Indefinite Delivery Contract
- SPE2DB25D3109-SPE2DB25FPKQEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $18,364.76 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/ml syringes. This firm fixed price contract, awarded on June 17, 2025, with an ultimate completion date of June 18, 2025, represents a competitively awarded non-set-aside procurement. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive $999,999,999.00 global pharmaceutical support vehicle running through December 2026 that enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's portfolio with the DLA encompasses specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The delivery of ENBREL, a biologic immunosuppressant medication used to treat rheumatoid arthritis and other inflammatory conditions, exemplifies the company's role in supplying specialized pharmaceutical commodities to support military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.4k | 6/17/25 |